Form 4 for CADL Candel Therapeutics, Inc.
Accepted 2022-05-10 00:00:00 ET · period of report 2022-05-06 · accession 0000899243-22-017474 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-05-10 | 2022-05-06 | CADL | Aguilar-Cordova Estuardo | Dir, 10% | M - OptEx | $1.46 | +135.2K | 1.15M | +13% | +$197.4K |
| D | 2022-05-10 | 2022-05-06 | CADL | Aguilar-Cordova Estuardo | Dir, 10% | F - Tax | $3.65 | -54.1K | 1.10M | -5% | -$197.4K |
| DM | 2022-05-10 | 2022-05-06 | CADL | Aguilar-Cordova Estuardo | Dir, 10% | M - OptEx | $0.00 | -135.2K | 30.5K | -82% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-06 | M | A | 135,183 | $1.46 | 1,151,106 | D | — | — | (F1) Includes 32,399 shares of common stock held jointly with spouse. |
| 2 | Common | Common Stock | 2022-05-06 | F | D | 54,074 | $3.65 | 1,097,032 | D | — | — | (F1) Includes 32,399 shares of common stock held jointly with spouse. |
| 3 | Derivative | Stock Option (Right to Buy) | 2022-05-06 | M | D | 76,717 | $0.00 | 0 | D | $1.46 · — to 2023-11-13 | 76,717 Common Stock | (F4) This option is fully vested and exercisable as of the date hereof. |
| 4 | Derivative | Stock Option (Right to Buy) | 2022-05-06 | M | D | 12,205 | $0.00 | 0 | D | $1.46 · — to 2028-08-17 | 12,205 Common Stock | (F4) This option is fully vested and exercisable as of the date hereof. |
| 5 | Derivative | Stock Option (Right to Buy) | 2022-05-06 | M | D | 46,261 | $0.00 | 30,456 | D | $1.46 · — to 2023-11-13 | 46,261 Common Stock | (F5) Includes options that were previously subject to performance vesting criteria. Upon the Reporting Person's termination as an officer of the Issuer, the vesting conditions were waived, and the shares underlying this option became fully vested and exercisable. (F4) This option is fully vested and exercisable as of the date hereof. |